Biogen writes off $233M of Aduhelm inventory
https://www.fiercepharma.com/pharma/biogen-files-233-million-aduhelm-write-wake-aduhelm-overhaul
Biogen is trying to escape the dark Aduhelm cloud hanging over its Alzheimer's disease drug launch. So far, the launch has triggered layoffs, a CEO switch and much more.
Now, Biogen has quietly unveiled a sizable inventory write-off. In a recent Securities and Exchange Commission (SEC) filing, the company said its Aduhlem inventories as of June 30 were "de minimis," or functionally worthless. That was $233 million lower than at the end of 2021, meaning the company wrote off the remaining value of its Aduhlem inventories in the first half of this year.
https://www.fiercepharma.com/pharma/biogen-files-233-million-aduhelm-write-wake-aduhelm-overhaul
Biogen is trying to escape the dark Aduhelm cloud hanging over its Alzheimer's disease drug launch. So far, the launch has triggered layoffs, a CEO switch and much more.
Now, Biogen has quietly unveiled a sizable inventory write-off. In a recent Securities and Exchange Commission (SEC) filing, the company said its Aduhlem inventories as of June 30 were "de minimis," or functionally worthless. That was $233 million lower than at the end of 2021, meaning the company wrote off the remaining value of its Aduhlem inventories in the first half of this year.